SIRT1 and female reproductive organ cancer: Overcoming these hurdles will require the development of more selective and potent compounds, improved patient stratification using molecular markers, and well-designed, longer-term clinical studies to fully realize the potential of SIRT1-targeted therapies in breast and gynecologic cancers.